All services

In vitro evaluation of bactericidal and bacteriostatic compounds using airway tissues

MucilAir™ and SmallAir™ are efficient models to study host-pathogen interactions and evaluate antibiotics toxicity and efficacy

Respiratory bacterial infections cause mild to severe diseases worldwide, such as pharyngitis, sinusitis, bronchitis, bronchiolitis and pneumonia, which are associated with huge costs for society.

Relevant human models are mandatory to test new molecules for shortening and alleviating these diseases, or to develop new therapies.

MucilAir™ and SmallAir™ hold in vitro specific mechanisms to counter invaders comparable to the in vivo situation, such as mucus production, mucociliary clearance, and secretion of defensive molecules.

Contract us to evaluate the efficiency of your novel anti bacterial coumpounds on the following strains:

Pseudomonas aeruginosa

Haemophilus influenzae

Staphylococcus aureus

Streptococcus pneumoniae

Scanning electron microscopy of MucilAir™ co-infected by Pa and Sp

Efficient Replication of Pseudomonas aeruginosa

The quantification of Pa growth on MucilAir™ without (left) and with (right) Meronem Pa growth is slightly inhibited by the presence of Mucus whereas it is efficiently inhibited by Meronem treatment.

Cytotoxicity induced by Pseudomonas aeruginosa

Cytotoxic effect of Pa infection on MucilAir™ without (left) and with (right) Meronem

Mucus seemed to prevent cytotoxicity induced by Pa up to 72h. Meronem prevented cytotoxicity induced by Pa up to 72h

Evaluation of barrier function after Pa infection

Evaluation of barrier function on MucilAir™ after Pa infection without (left) and with (right) Meronem

Pa impaired the barrier function from 48h post inoculation without mucus. Presence of mucus protects the barrier function up to 48h. Meronem efficiently preserved the barrier function from Pa infection at all tested time points.

Interested in this service ?